AR112789A2 - COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA - Google Patents

COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA

Info

Publication number
AR112789A2
AR112789A2 ARP180102520A ARP180102520A AR112789A2 AR 112789 A2 AR112789 A2 AR 112789A2 AR P180102520 A ARP180102520 A AR P180102520A AR P180102520 A ARP180102520 A AR P180102520A AR 112789 A2 AR112789 A2 AR 112789A2
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
term
aryl
group
Prior art date
Application number
ARP180102520A
Other languages
English (en)
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR112789(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of AR112789A2 publication Critical patent/AR112789A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos tienen propiedades farmacéuticas potencialmente valiosas para el tratamiento de trastornos cardiovasculares tales como la hipertensión y la insuficiencia cardíaca crónica. Reivindicación 1: Un compuesto de fórmula (1), donde R¹, R² y R³ son iguales o diferentes y significan un grupo hidrógeno, halógeno, alquilo, nitro, amino, alquilcarbonilamino, alquilamino o dialquilamino; R⁴ significa -alquil-arilo o -alquil-heteroarilo; X significa CH₂, un átomo de oxígeno o un átomo de azufre; n es 2 ó 3; los enantiómeros (R) y (S) individuales o mezclas de enantiómeros del mismo; o sales o ésteres farmacéuticamente aceptables del mismo, en donde el término alquilo significa cadenas de hidrocarburo, rectas o ramificadas, que contienen de uno a seis átomos de carbono, opcionalmente sustituidas con grupos arilo, alcoxi, halógeno, alcoxicarbonilo o hidroxicarbonilo; el término arilo significa un grupo fenilo o naftilo, opcionalmente sustituido con un grupo alquilo, alquiloxi, halógeno o nitro; el término halógeno significa flúor, cloro, bromo o yodo; el término heteroarilo significa un grupo heteroaromático.
ARP180102520A 2007-05-08 2018-09-05 COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA AR112789A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds

Publications (1)

Publication Number Publication Date
AR112789A2 true AR112789A2 (es) 2019-12-11

Family

ID=38198874

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101912A AR066457A1 (es) 2007-05-08 2008-05-06 Derivados de imidazol, procesos de obtencion, composiciones farmaceuticas y usos.
ARP180102520A AR112789A2 (es) 2007-05-08 2018-09-05 COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080101912A AR066457A1 (es) 2007-05-08 2008-05-06 Derivados de imidazol, procesos de obtencion, composiciones farmaceuticas y usos.

Country Status (30)

Country Link
US (5) US8481582B2 (es)
EP (1) EP2155731B1 (es)
JP (1) JP5559677B2 (es)
KR (1) KR101598482B1 (es)
CN (1) CN101687858B (es)
AR (2) AR066457A1 (es)
AT (1) ATE499367T1 (es)
AU (1) AU2008246443B2 (es)
BR (1) BRPI0811275B8 (es)
CA (1) CA2686387C (es)
CL (1) CL2008001321A1 (es)
CY (1) CY1111517T1 (es)
DE (1) DE602008005141D1 (es)
DK (1) DK2155731T3 (es)
ES (1) ES2360841T3 (es)
GB (1) GB0708818D0 (es)
HK (1) HK1142898A1 (es)
HR (1) HRP20110253T1 (es)
IL (1) IL201921A (es)
MX (1) MX2009012041A (es)
NO (1) NO20093275L (es)
NZ (1) NZ580962A (es)
PL (1) PL2155731T3 (es)
RS (1) RS51692B (es)
RU (1) RU2501796C2 (es)
SI (1) SI2155731T1 (es)
TW (1) TWI458722B (es)
UA (1) UA104844C2 (es)
WO (1) WO2008136695A1 (es)
ZA (1) ZA200908612B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
PT2655363T (pt) 2010-12-22 2017-07-13 Bial-Portela & Ca S A Formas cristalinas e processos para a sua preparação
EP2726454B1 (en) * 2011-06-29 2018-01-24 Bial-Portela & CA, S.A. Process
CA2890920C (en) 2012-11-14 2020-12-15 Bial - Portela & Ca, S.A. 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
TWI790281B (zh) 2017-09-13 2023-01-21 美商安進公司 雙醯胺肌節活化化合物及其用途
US11434242B2 (en) 2017-12-04 2022-09-06 Bial—Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
WO1995029165A2 (en) * 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
US20170369478A1 (en) 2017-12-28
IL201921A0 (en) 2010-06-16
CA2686387C (en) 2015-06-30
AU2008246443A8 (en) 2010-01-07
IL201921A (en) 2013-11-28
NZ580962A (en) 2012-05-25
TW200918525A (en) 2009-05-01
KR20100017546A (ko) 2010-02-16
MX2009012041A (es) 2010-02-18
US20210261533A1 (en) 2021-08-26
ATE499367T1 (de) 2011-03-15
US8481582B2 (en) 2013-07-09
AU2008246443B2 (en) 2013-07-11
DE602008005141D1 (de) 2011-04-07
ES2360841T3 (es) 2011-06-09
RU2009145270A (ru) 2011-06-20
ZA200908612B (en) 2010-11-24
US9630951B2 (en) 2017-04-25
DK2155731T3 (da) 2011-05-02
US20130345275A1 (en) 2013-12-26
RU2501796C2 (ru) 2013-12-20
JP2010526136A (ja) 2010-07-29
HK1142898A1 (en) 2010-12-17
EP2155731A1 (en) 2010-02-24
NO20093275L (no) 2010-02-04
EP2155731B1 (en) 2011-02-23
CN101687858A (zh) 2010-03-31
CN101687858B (zh) 2012-12-26
CY1111517T1 (el) 2015-08-05
KR101598482B1 (ko) 2016-02-29
BRPI0811275B8 (pt) 2021-05-25
AR066457A1 (es) 2009-08-19
US20190322648A1 (en) 2019-10-24
WO2008136695A1 (en) 2008-11-13
US20100137390A1 (en) 2010-06-03
BRPI0811275B1 (pt) 2020-01-07
BRPI0811275A2 (pt) 2014-12-23
JP5559677B2 (ja) 2014-07-23
HRP20110253T1 (hr) 2011-05-31
CL2008001321A1 (es) 2008-12-26
UA104844C2 (uk) 2014-03-25
AU2008246443A1 (en) 2008-11-13
SI2155731T1 (sl) 2011-05-31
TWI458722B (zh) 2014-11-01
PL2155731T3 (pl) 2011-07-29
GB0708818D0 (en) 2007-06-13
RS51692B (en) 2011-10-31
CA2686387A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
AR112789A2 (es) COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA
ES2585330T3 (es) Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR083542A1 (es) Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201071078A1 (ru) Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение
AR059590A1 (es) Inhibidores de quinasa basados en la hidantoina
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
MY169179A (en) Novel piperidine compound or salt thereof
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
MX2009009384A (es) Malonamidas como antagonistas de orexina.
MY162998A (en) Ethynyl derivatives
MX2016002738A (es) Compuestos farmaceuticos.
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
HK1155739A1 (en) A benzimidazole derivative as a calcium channel blocker
BR112012023412A2 (pt) composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
CO6801735A2 (es) Derivados de pirazolidin-3-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure